REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses low-dose chemo and radiation before a donor stem cell infusion, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New hope for chinese patients with stubborn multiple myeloma
Disease control CompletedThis study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that stopped responding to standard treatments. The drug works by helping the body's immune system attack the cancer cells. The goal was to see if it is safe and can shrink or control the can…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New combo therapy shows promise for Hard-to-Treat myeloma
Disease control CompletedThis study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the treatment control…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New antibody therapy shows promise for Hard-to-Treat myeloma
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had come back or stopped responding to other treatments. The drug is a bispecific antibody that helps the immune system attack cancer cells. The goal was to check safety and see if the drug could…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo tackles tough myeloma in early trial
Disease control CompletedThis early-phase study tested a three-drug combination (ibrutinib, lenalidomide, and dexamethasone) in 14 people whose multiple myeloma had returned or stopped responding to treatment. The main goal was to find safe doses and identify side effects. While the approach aims to cont…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control CompletedThis early-phase study tested a combination of three drugs (selinexor, carfilzomib, and dexamethasone) in 52 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and identify side effects. Researchers …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 18, 2026 12:00 UTC